Tau PET imaging in cognitively normal elderly subjects: A twin approach - Tau Twin

Amsterdam UMC VUmc0 个研究点目标入组 80 人开始时间: 2018年12月19日最近更新: 2021年4月5日

适应症

试验速览

暂无简介。

•Inclusion in PreclinAD study (2014.210) and a subject must be older than 60 years and have received an [18F]flutemetamol amyloid PET scan and/or have a known amyloid status obtained from CSF.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 70

•1.Has contra indications for MRI scanning and therefore has not received brain MRI;
•2.Has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with interpretation of PET scan;
•4.Has a relevant history of severe drug allergy or hypersensitivity. Relevant severe drug allergies should be determined by the Principal Investigator or Co-Principal Investigator, and any questions about a subject’s eligibility can be directed to Avid Radiopharmaceuticals Inc.;
•5.Has ever participated in an experimental study with a tau agent, unless it can be documented that the subject received only placebo during the course of the trial;
•6.Has been injected with a previously administered radiopharmaceutical within 6 terminal half-lives or when total yearly radiation exposure exceeds 16.1 mSv for female and 22.4 mSv for male participants[25].
•7.Has a history of severe traumatic brain injury (TBI).

发起方

Amsterdam UMC VUmc